Clinicopathological features and prognostic factors of Japanese patients with “peripheral T-cell lymphoma, unspecified” diagnosed according to the WHO classification

Clinicopathological features and prognostic factors of Japanese patients with “peripheral T-cell lymphoma, unspecified” diagnosed according to the WHO classification

Clinicopathological features of 36 patients, male: 58.3%; median: 68 years, with “peripheral T-cell lymphoma, unspecified” diagnosed by the WHO criteria were reviewed. Majority (69.4%) had stage IV disease with frequent involvements into bone marrow, spleen, liver, and skin. According to the IPI, 72...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research Vol. 28; no. 12; pp. 1287 - 1292
Main Authors: Kojima, Hiroshi, Hasegawa, Yuichi, Suzukawa, Kazumi, Mukai, Harumi Y., Kaneko, Shin, Kobayashi, Toshitaka, Kamoshita, Masaharu, Shinagawa, Atsushi, Komeno, Takuya, Komatsu, Tsunehiko, Mitsuhashi, Shoichi, Kawachi, Yasuhiro, Yamashita, Yoriko, Mori, Naoyoshi, Nagasawa, Toshiro
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-12-2004
Subjects:
Adult
Aged
CD4-CD8 Ratio
Classification
Clinicopathological features
Cytotoxic T-cell lymphoma
Female
Humans
Immunohistochemistry
Japan
Lymphoma, T-Cell, Peripheral - classification
Lymphoma, T-Cell, Peripheral - diagnosis
Lymphoma, T-Cell, Peripheral - drug therapy
Male
Middle Aged
Peripheral T-cell lymphoma, unspecified
Prognosis
Remission Induction
Retrospective Studies
Risk Factors
Survival
Survival Rate
T-Lymphocytes, Cytotoxic
Treatment Outcome
World Health Organization
Japan
Clinicopathological features
Cytotoxic T-cell lymphoma
Survival
Peripheral T-cell lymphoma, unspecified
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinicopathological features of 36 patients, male: 58.3%; median: 68 years, with “peripheral T-cell lymphoma, unspecified” diagnosed by the WHO criteria were reviewed. Majority (69.4%) had stage IV disease with frequent involvements into bone marrow, spleen, liver, and skin. According to the IPI, 72.2% were categorized as high or high-intermediate risk group. CR and PR were achieved in 12 and 10 out of 31 patients treated by CHOP-based chemotherapy, respectively. One- and two-year overall survivals were 60.6 and 25.0%, respectively. Performance status, serum LDH, and B symptom were significant prognostic factors. Survival of CD4−/CD8+ cases, corresponding to cytotoxic T-cell lymphoma, was significantly worse than that of CD4+/CD8−.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2004.04.016